(0.22%) 5 472.56 points
(0.59%) 39 349 points
(0.11%) 17 752 points
(0.75%) $82.15
(-1.61%) $2.56
(-0.13%) $2 336.50
(-0.03%) $29.55
(-0.23%) $999.60
(-0.36%) $0.930
(-0.49%) $10.62
(-0.26%) $0.789
(2.08%) $87.51
Live Chart Being Loaded With Signals
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer...
Stats | |
---|---|
今日成交量 | 818 |
平均成交量 | 12 788 |
市值 | 16.62M |
Last Dividend | $1.853 ( 2021-12-29 ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 0 (Industry) 0 |
ATR14 | $0.0440 (0.32%) |
Financial Reports:
No articles found.
Loncar Cancer Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.106 | 2015-12-29 |
Last Dividend | $1.853 | 2021-12-29 |
Next Dividend | $0 | N/A |
Payout Date | 2021-12-31 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $2.60 | -- |
Avg. Dividend % Per Year | 0.86% | -- |
Score | 0.59 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2015 | $0.106 | 0.42% |
2016 | $0 | 0.00% |
2017 | $0.350 | 1.62% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0.288 | 1.23% |
2021 | $1.853 | 5.87% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
29 Dec 2021 | $1.853 | 28 Dec 2021 | 30 Dec 2021 | 31 Dec 2021 |
30 Dec 2020 | $0.288 | 29 Dec 2020 | 31 Dec 2020 | 04 Jan 2021 |
28 Dec 2017 | $0.350 | 28 Dec 2017 | 29 Dec 2017 | 02 Jan 2018 |
29 Dec 2015 | $0.106 | 30 Nov -0001 | 31 Dec 2015 | 04 Jan 2016 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | 10.00 | 10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | 10.00 | 8.00 | [0.5 - 2] |
Total Score | 0 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 0 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Loncar Cancer
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。